Grey Wolf Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Grey Wolf Therapeutics's estimated annual revenue is currently $2.9M per year.
- Grey Wolf Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Grey Wolf Therapeutics has 37 Employees.
- Grey Wolf Therapeutics grew their employee count by 42% last year.
Grey Wolf Therapeutics's People
Name | Title | Email/Phone |
---|
Grey Wolf Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.2M | 15 | 50% | N/A | N/A |
#2 | $0.3M | 4 | 0% | N/A | N/A |
#3 | $0.9M | 11 | 0% | N/A | N/A |
#4 | $2.9M | 37 | 42% | N/A | N/A |
What Is Grey Wolf Therapeutics?
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery. For more information, visit the website or email enquiries@gwt.bio.
keywords:N/AN/A
Total Funding
37
Number of Employees
$2.9M
Revenue (est)
42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.7M | 38 | 9% | N/A |
#2 | $8.8M | 38 | 19% | N/A |
#3 | $35M | 39 | 5% | N/A |
#4 | $4.6M | 40 | 21% | N/A |
#5 | $9.1M | 42 | 5% | N/A |